Immunology and Inflammation Correction for “Protectin D1n-3 DPA and resolvin D5n-3 DPA are effectors of intestinal protection,” by Thomas Gobbetti, Jesmond Dalli, Romain A. Colas, Donata Federici Canova, Marius Aursnes, Delphine Bonnet, Laurent Alric, Nathalie Vergnolle, Celine Deraison, Trond V. Hansen, Charles N. Serhan, and Mauro Perretti, which was first published March 29, 2017; 10.1073/pnas.1617290114 (Proc. Natl. Acad. Sci. U.S.A. 114, 3963–3968).
The authors note that the legend for Fig. 1 appeared incorrectly. Fig. 1A was conducted using bowel tissue resections, not biopsies. The figure and its corrected legend appear below. The online version has been corrected.
Fig. 1.
Tissue samples were obtained from control and IBD patients (SI Appendix, Table S1 for demographic information). (A) H&E staining of resections of human bowel tissues. (Magnification: 20×.) (B–F) Analyses in biopsies of human bowel tissues. SPM profiles were obtained using LC-MS-MS based lipid mediator profiling. (B) Schematic of multiple reaction monitoring (MRM) chromatograms for identified mediators. (C) Representative MS/MS spectra employed for the identification of n-3 DPA resolvin D5 (RvD5n-3 DPA, 7S,17S-dihydroxydocosa--8E,10Z,13Z,15E,19Z-pentaenoic acid), n-3 DPA protectin D1 (PD1n-3 DPA, 10R,17S-dihydroxydocosa-7Z,11E,13E,15Z,19Z-pentaenoic acid), and 15-epi Lipoxin A4 (5S,6R,15R-trihydroxyeicosa-7E,9E,11Z,13E-tetraenoic acid). Results are representative of n = 30 colon biopsies (SI Appendix, Table S2). (D–F) Quantification of RvD5n-3 DPA, PD1n-3 DPA, and 10S,17S-diHDHA in the tissue samples. *P < 0.05 vs. healthy tissue.
The authors also note that the legend for SI Appendix, Fig. S1 appeared incorrectly. The illustrations where the multiple reaction monitoring (MRM) chromatograms are presented were schematics. The SI Appendix has been corrected online.